(RTW) |
| 0 (0%) 01-13 20:28 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.44 |
| Resistance 1: | 0.35 |
| Pivot price: | 0.26 |
| Support 1: | 0.19 |
| Support 2: | 0.16 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 4.756 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Tue, 13 Jan 2026
Morning briefing: RTW backs first biotech flotation of 2026; Herald publishes circular for Saba tender offer; British Land boss takes P3 job; plus ONWD, HICL, ASLI - QuotedData
Tue, 16 Dec 2025
RTW startup signs autoimmune antibody pact with China’s GenSci - Endpoints News
Tue, 16 Dec 2025
RTW Veteran Center to open in DeKalb’s Junction Shopping Center - Shaw Local
Tue, 16 Dec 2025
GenSci and RTW Investments Announce Strategic Partnership on Anti-TSHR Antibody GS-098 (YB-101) for Graves’ Disease and Thyroid Eye Disease, With Global Ex-China Development Being Led by Yarrow Bioscience - BioSpace
Thu, 06 Nov 2025
Evommune announces $150 million IPO - 07:00:10 06 Nov 2025 - RTW News article - London Stock Exchange
Fri, 31 Oct 2025
Latham & Watkins Advises RTW Investments in US$75 Million Royalty Funding Agreement With Savara - Latham & Watkins LLP
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
